Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

L. Herrera, C. Stanciu-Herrera, C. Morgan, V. Ghetie, E. S. Vitetta

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

Original languageEnglish (US)
Pages (from-to)2380-2387
Number of pages8
JournalLeukemia and Lymphoma
Volume47
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Immunotoxins
SCID Mice
Vincristine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
B-Cell Leukemia
Daunorubicin
Survivors

Keywords

  • Chemotherapy
  • Childhood leukemia
  • Immunotherapy
  • Immunotoxins
  • Monoclonal antibodies
  • Pre-B ALL

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia. / Herrera, L.; Stanciu-Herrera, C.; Morgan, C.; Ghetie, V.; Vitetta, E. S.

In: Leukemia and Lymphoma, Vol. 47, No. 11, 11.2006, p. 2380-2387.

Research output: Contribution to journalArticle

@article{f693f0a85e694dda916e57f3e0944970,
title = "Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia",
abstract = "The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80{\%} of the mice treated with IT plus vincristine were long-term survivors.",
keywords = "Chemotherapy, Childhood leukemia, Immunotherapy, Immunotoxins, Monoclonal antibodies, Pre-B ALL",
author = "L. Herrera and C. Stanciu-Herrera and C. Morgan and V. Ghetie and Vitetta, {E. S.}",
year = "2006",
month = "11",
doi = "10.1080/10428190600821989",
language = "English (US)",
volume = "47",
pages = "2380--2387",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia

AU - Herrera, L.

AU - Stanciu-Herrera, C.

AU - Morgan, C.

AU - Ghetie, V.

AU - Vitetta, E. S.

PY - 2006/11

Y1 - 2006/11

N2 - The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

AB - The anti-CD19 immunotoxin (IT) (HD37-dgRTA) is effective in killing B-lineage leukemia cells and in curing severe combined immunodeficient mice with acute lymphoblastic leukemia. The present study aimed to identify effective combinations of HD37-dgRTA and chemotherapeutic agents. The in-vitro cytotoxicity assays demonstrate that the combination of HD37-dgRTA and either daunorubicin or vincristine is effective. The in-vivo experiments using HD37-dgRTA with vincristine prolonged the survival of mice compared to the chemotherapeutic agent or IT (90.7 vs. 147.1 days). Also, 80% of the mice treated with IT plus vincristine were long-term survivors.

KW - Chemotherapy

KW - Childhood leukemia

KW - Immunotherapy

KW - Immunotoxins

KW - Monoclonal antibodies

KW - Pre-B ALL

UR - http://www.scopus.com/inward/record.url?scp=33751101580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751101580&partnerID=8YFLogxK

U2 - 10.1080/10428190600821989

DO - 10.1080/10428190600821989

M3 - Article

C2 - 17107913

AN - SCOPUS:33751101580

VL - 47

SP - 2380

EP - 2387

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -